Impact of renal function impairment on kappa free light chain index
CSF κ-FLC concentration is not directly affected by renal function. The κ-FLC index compensates for renal function effects by factoring in serum κ-FLC concentration and Q<sub>alb</sub>. κ-FLC index can be interpreted without considering renal function.
Authors
- Janette Walde (ORCID: https://orcid.org/0000-0002-1241-5292)
- Franziska Di Pauli (ORCID: https://orcid.org/0000-0001-6183-2394)
- Robert Barket (ORCID: https://orcid.org/0000-0001-6909-6109)
- Harald Hegen
- Anne Zinganell (ORCID: https://orcid.org/0000-0002-4664-9310)
- Gabriel Bsteh (ORCID: https://orcid.org/0000-0002-0825-0851)
- Michael Auer (ORCID: https://orcid.org/0000-0002-5117-4225)
- Markus Ponleitner (ORCID: https://orcid.org/0000-0002-3709-1845)
- Florian Deisenhammer (ORCID: https://orcid.org/0000-0003-4541-8841)
- Nik Krajnc (ORCID: https://orcid.org/0000-0002-4146-5870)
- Tobias Zrzavy (ORCID: https://orcid.org/0000-0001-8909-1591)
- Klaus Berek (ORCID: https://orcid.org/0000-0003-2755-2043)
- Fabian Föttinger (ORCID: https://orcid.org/0009-0005-7970-5349)
- Martin Schmidauer (ORCID: https://orcid.org/0009-0007-3081-854X)
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1515/cclm-2025-0007
- Citations
- 2
- Primary Topic
- Electrolyte and hormonal disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- European Committee for Treatment and Research in Multiple Sclerosis